Cite
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial
MLA
Viktor Stus, et al. “Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.” Clinical Genitourinary Cancer, vol. 15, no. 1, Feb. 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b3927d47e887b92d848b304a0c36fa73&authtype=sso&custid=ns315887.
APA
Viktor Stus, Thomas E. Hutson, Yaroslav Shparyk, Glen Ian Andrews, Angel H. Bair, Oleg Lipatov, Nicholas J. Vogelzang, Salman Al-Shukri, & Brad Rosbrook. (2016). Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clinical Genitourinary Cancer, 15(1).
Chicago
Viktor Stus, Thomas E. Hutson, Yaroslav Shparyk, Glen Ian Andrews, Angel H. Bair, Oleg Lipatov, Nicholas J. Vogelzang, Salman Al-Shukri, and Brad Rosbrook. 2016. “Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.” Clinical Genitourinary Cancer 15 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b3927d47e887b92d848b304a0c36fa73&authtype=sso&custid=ns315887.